Info@ThinkPinkRocks.org

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer’s disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

Visit site:
EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer’s disease

Scroll to Top